x
Filter:
Filters applied
- Molecular Bases of Disease
- Aschner, MichaelRemove Aschner, Michael filter
- glutamateRemove glutamate filter
Publication Date
Please choose a date range between 2015 and 2020.
Molecular Bases of Disease
2 Results
- Molecular Bases of DiseaseOpen Access
Astrocyte-specific deletion of the transcription factor Yin Yang 1 in murine substantia nigra mitigates manganese-induced dopaminergic neurotoxicity
Journal of Biological ChemistryVol. 295Issue 46p15662–15676Published online: September 6, 2020- Edward Pajarillo
- James Johnson Jr.
- Asha Rizor
- Ivan Nyarko-Danquah
- Getinet Adinew
- Julia Bornhorst
- and others
Cited in Scopus: 20Manganese (Mn)-induced neurotoxicity resembles Parkinson's disease (PD), but the mechanisms underpinning its effects remain unknown. Mn dysregulates astrocytic glutamate transporters, GLT-1 and GLAST, and dopaminergic function, including tyrosine hydroxylase (TH). Our previous in vitro studies have shown that Mn repressed GLAST and GLT-1 via activation of transcription factor Yin Yang 1 (YY1). Here, we investigated if in vivo astrocytic YY1 deletion mitigates Mn-induced dopaminergic neurotoxicity, attenuating Mn-induced reduction in GLAST/GLT-1 expression in murine substantia nigra (SN). - Molecular Bases of DiseaseOpen Access
Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1)
Journal of Biological ChemistryVol. 290Issue 39p23725–23737Published online: August 12, 2015- Pratap Karki
- Clifford Kim
- Keisha Smith
- Deok-Soo Son
- Michael Aschner
- Eunsook Lee
Cited in Scopus: 47Background: The mechanism for transcriptional regulation of EAAT1 remains to be elucidated.Results: EGF-activated NF-κB is a positive regulator of EAAT1, whereas manganese-activated YY1, with HDACs acting as co-repressors, is a negative regulator.Conclusion: NF-κB and YY1 are two critical transcriptional regulators of EAAT1.Significance: Identifying the molecular targets of EAAT1 regulation is crucial to develop therapeutics against neurological disorders associated with impairment of EAAT1.